New drug may help keep leukemia away after transplant
NCT ID NCT03728335
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug enasidenib can safely prevent leukemia from returning in 35 people with IDH2-mutated acute myeloid leukemia who have already had a donor stem cell transplant. Enasidenib works by blocking enzymes that cancer cells need to grow. The main goal is to check for side effects, with additional goals of measuring overall survival and time to relapse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Moffitt Cancer Center
ACTIVE_NOT_RECRUITINGTampa, Florida, 33612, United States